IndiGo Q4 FY24 results: The company reported a 25.9% year-on-year growth in revenue from operations at Rs 17,825.27 crore, from Rs 14,160.6 crore
The company also announced the commencement of operations at their newly acquired hospital in Faridabad, strengthening its presence in the Delhi NCR market
Skincare firm Mamaearth's parent posted a near 22% rise in revenue from operations to Rs 471 crore
ITC Q4FY24 results: The company board recommended a final dividend of Rs 7.50 per ordinary share of Rs 1 each for the financial year that ended on March 31, 2024
Soaring inventory costs hit Page Industries' bottom-line even as post-COVID demand for its innerwear and athleisure collections stayed steady
Stock market LIVE updates on Thursday, May 23, 2024: In the broader markets, the S&P BSE MidCap index hit a new high of 43,442.5, while the S&P BSE SmallCap index touched a new lifetime high of 48,229
This marks a second consecutive quarter of revenue growth for Lenovo after it suffered five straight quarters of revenue declines amid the post-COVID slowdown
The management guided for high single digit revenue growth in FY25 factoring in the impact of US site compliance issues.
GMM Pfaudler's consolidated net profit dropped 14 per cent to Rs 28.7 crore in Q4FY24, from Rs 33.3 crore in the same quarter a year ago (Q4FY23)
IndiGo Q4 results: Analysts expect robust demand, and lower competitive intensity to aid Q4Fy24 earnings
Aditya Birla Group flagship holding firm Grasim Industries Ltd has reported an increase of 15.54 per cent in consolidated net profit at Rs 2,721.81 crore for the fourth quarter ended March 2024, led by strong performance by its cement and financial services business. The company had posted a net profit of Rs 2,355.67 crore during the January-March quarter a year ago, according to a late night regulatory filing by Grasim Industries on Wednesday. Its revenue from operations was up 12.74 per cent to Rs 37,727.13 crore during the quarter under review. It was at Rs 33,462.14 crore in the corresponding period of the previous fiscal. The consolidated revenue was "at its highest levels," said an earning statement from Grasim Industries. Grasim has an exceptional items charge of Rs 538 crore in the March quarter. Its consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) for the quarter stood "at an all-time high" of Rs 6,196 crore, recording a growth of 27 pe
Company Q4 FY24 results today: ICRA, Rupa & Company, Page Industries, and Shilpa Medicare will also release their fourth quarter earnings report on May 23
ITC Q4 results: ITC may report a flattish quarter with steady cigarette volume, weak paper volumes, offset by healthy hospitality sales revenue
Shares of shipbuilding firms in India soared to record high levels in trades on Thursday after Garden Reach Shipbuilders reported strong Q4 earnings.
On Wednesday, Gland Pharma reported a two fold jump or 145 per cent increase in consolidated net profit, reaching Rs 192.4 crore for the January-March period of FY24
All you need to know before the market opens on Thursday: Gift Nifty hints tepid start; IT stocks likely to be in focus post Nvidia earnings; ITC, IndiGo also to report March quarter results today.
The fall came after the company announced its Q4 results, which missed street expectations.
Gland Pharma on Wednesday said its consolidated profit after tax (PAT) surged over two-fold to Rs 192 crore for the March quarter. The company has reported a PAT of Rs 79 crore in the year-ago period, the Hyderabad-based drug firm said in a statement. Revenue from operations rose to Rs 1,537 crore in the fourth quarter of FY24 as against Rs 785 crore in the year-ago period, it said. For the year ended March 31, 2024, the company reported a PAT of Rs 772 crore as against Rs 781 crore in 2022-23 fiscal. Revenue from operations rose to Rs 5,665 crore last fiscal as against Rs 3,625 crore in FY23. "This year marked a significant rebound for our base business, and we began an exciting new chapter as we completed our first international acquisition, Cenexi, in Europe," Gland Pharma MD and CEO Srinivas Sadu said. Despite the dynamic business landscape, the drugmaker has shown resilience and delivered a performance that positions it well for continued growth and success, he added. "We s
Grasim Q4 results: The board recommended dividend of Rs 10 per equity share for FY24
Firm guides for high single-digit top line, higher R&D spend in FY25; board approves appointment of Dilip Shanghvi as chairman